Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4+ T cells from virus-induced depletion in SCID mice transplanted with human cells

Virology

Volumn 263, Issue 1, 1999, Pages 78-88

  Lapenta, Caterina ^a   Santini, Stefano M ^a   Proietti, Enrico ^a   Rizza, Paola ^a   Logozzi, Mariantonia ^a   Spada, Massimo ^a   Parlato, Stefania ^a   Fais, Stefano ^a   Pitha, Paula M ^b   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSPLANTATION; COMBINED IMMUNODEFICIENCY; DRUG EFFECT; FEMALE; HELPER CELL; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTION RESISTANCE; INTERFERON PRODUCTION; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033543965     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9869     Document Type: Article

References (43)

1. Alton K., Stabinsky Y., Richards R., Ferguson B., Goldstein L., Altrock B., Miller L., Stebbings N. Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-γ analogs. De Maeyer E., Schellenkens H. The Biology of the Interferon System. 1983;119-128 Elsevier, Amsterdam.
2. Ausiello C. M., Sestili P., Locardi C., Logozzi M., Rizza P., Parlanti E., Yang L., Modica A., Modesti A., Musiani P., Kaido T. J., Rozera C., Buttò S., Belardelli F. Defective response to T-cell mitogens in mice injected with human immunodeficiency virus type 1-infected U937 cells. J. Gen. Virol. 75:1994;2789-2794.
3. Bednarik D. P., Mosca J. D., Raj N. B. K., Pitha P. M. Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated α2-interferon. Proc. Natl. Acad. Sci. USA. 86:1989;4958-4962.
4. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS. 103:1995;161-179.
5. Belardelli F., Gresser I. The neglected role of type I interferon in the T cell response: Implications for its clinical use. Immunol. Today. 17:1996;369-372.
6. + T cells after injection of tumor cells expressing IFN-α into syngeneic mice. Cancer Res. 58:1998;5795-5802.
7. Dolei A., Fattorossi A., D'Amelio R., Aiuti F., Dianzani F. Direct and cell-mediated effects of interferon-α and -γ on cells chronically infected with HTLV-III. J. Interferon Res. 6:1986;543-549.
8. Fall L. S., M'Bika J. P., Le Coq H., Fouchard M., Astgen A., Bizzini B., Gringeri A., Santagostino E., Burny A., Zagury D. Biological effect of active anti-IFN alpha immunization in HIV-infected patients. Biomed. Pharmacother. 49:1995;422-428.
9. + cell counts >150 × 10(6)/L: Results of the Zidon trial. Zidon Study Group. AIDS. 9:1995;1025-1035.
10. Folks T. M., Powell D., Lightfoote M., Koening S., Fauci A. S., Benn S., Robson A., Daugherty D., Gendelman H. E., Hoggan M. D., Venkayesan S., Martin M. A. Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus. J. Exp. Med. 164:1986;280-290.
11. Frissen P. H., van der Ende M. E., ten Napel C. H., Weigel H. M., Schreij G. S., Kauffmann R. H., Koopmans P. P., Hoepelman A. I., de Boer J. B., Weverling G. J. Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. J. Infect. Dis. 169:1994;1351-1355.
12. Gendelman H. E., Baca L. M., Turpin J., Kalter D. C., Hansen B., Orenstein J. M., Dieffenbach C. W., Friedman R. M., Meltzer M. S. Regulation of HIV replication in infected monocytes by IFN-α mechanisms for viral restriction. J. Immunol. 145:1990;2669-2676.
13. Gringeri A., Santagostino E., Mannucci P. M., Siracusano L., Marinoni A., Criscuolo M., Carcagno M., Fall L. S., M'Bika J. P., Bizzini B. Anti-alpha interferon immunization: Safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression. Cell. Mol. Biol. 41:1995;381-387.
14. Gringeri A., Santagostino E., Mannucci P. M., Tradati F., Cultraro D., Buzzi A., Criscuolo M., David A., Guillemot L., Barre-Sinoussi F. A randomized, placebo-controlled, blind anti-AIDS clinical trial: Safety and immunogenicity of a specific anti-IFN alpha immunization. J. Acquired Immun. Defic. Syndr. 7:1994;978-988.
15. Hartshorn K. L., Neumeyer D., Vogt M. W., Schooley R. T., Hirsch M. S. Activity of interferon alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res. Hum. Retroviruses. 3:1987;125-133.
16. Kornbluth R. S., Oh P. S., Munis J. R., Cleveland P. H., Richman D. D. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J. Exp. Med. 169:1989;1137-1151.
17. Kovacs J. A., Bechtel C. Jr., Davey R. T., Falloon J., Polis M. A., Walker R. E., Metcalf J. A., Davey V., Piscitelli S. C., Baseler M., Dewar R., Salzman N. P., Masur H., Lane H. C. Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: Results of a phase I/II trial. J. Infect. Dis. 173:1996;840-848.
18. Lachgar A., Bizzini B. Involvement of alpha-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment. Biomed. Pharmacother. 48:1994;73-77.
19. Lane H. C., Davey V., Kovacs J. A., Feinberg J., Metcalf J. A., Herpin B., Walker R., Deyton L. Jr., Davey R. T., Falloon J. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann. Intern. Med. 112:1990;805-811.
20. Lane H. C., Kovacs J. A., Feinberg J., Herpin B., Davey V., Walker R., Deyton L., Metcalf J. A. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 2:1988;1218-1222.
21. Lapenta C., Fais S., Rizza P., Spada M., Logozzi M., Parlato S., Santini S. M., Pirillo M., Belardelli F., Proietti E. U937-SCID mouse xenografts: A new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. Antiviral Res. 36:1997;81-90.
22. Lau A. S., Williams B. R. The role of interferon and tumor necrosis factor in the pathogenesis of AIDS. J. Exp. Pathol. 5:1990;111-122.
23. Luft T., Pang K. C., Thomas E., Hertzog P., Hart D. N. J., Trapani J., Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161:1998;1947-1953.
24. Mosier D. E., Gulizia R. J., Baird S. M., Wilson D. B., Spector D. H., Spector S. A. Human immunodeficiency virus infection of human PBL-SCID mice. Science. 25:1991;791-794.
25. + T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science. 260:1993;689-692.
26. Oka S., Hirabayashi Y., Mouri H., Sakurada S., Goto H., Ohnishi K., Kimura S., Mitamura K., Shimada K. Beta-interferon and early stage HIV infection. J. Acquired Immun. Defic. Syndr. 2:1989;125-128.
27. Paquette R. L., Hsu N. C., Kiertscher S. M., Park A. N., Tran L., Roth M. D., Gaspy J. A. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukocyte Biol. 64:1998;358-367.
28. Poli G., Orestein J. M., Kinter A., Folks T. M., Fauci A. S. Interferon-α but not AZT suppresses HIV expression in chronically infected cell lines. Science. 244:1989;575-577.
29. Rivero J., Fraga M., Cancio L., Cuervo J., Lopez-Saura P. Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals. Biotherapy. 10:1997;107-113.
30. Rivero J., Limonta M., Aguilera A., Fraga M., Lopez Saura P. Use of recombinant interferon-alpha in human immunodeficiency virus (HIV)-infected individuals. Biotherapy. 8:1994;23-31.
31. Rizza P., Santini S. M., Logozzi M., Lapenta C., Sestili P., Gherardi G., Lande R., Spada M., Parlato S., Belardelli F., Fais S. T-cell dysfunction in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: In vivo effects of HIV on highly activated human immune cells. J. Virol. 70:1996;7958-7964.
32. Rogge L., Barberis-Maino L., Biffi M., Passini N., Presky D. H., Gubler U., Sinigaglia F. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 485:1997;825-831.
33. Romagnani S. Induction of Th1 and Th2 responses: A key role for the "natural" immune response. Immunol. Today. 13:1992;379-381.
34. Sanhadji K., Leissner P., Firouzi R., Pelloquin F., Kehrli L., Marigliano M., Calenda V., Ottmann M., Tardy J. C., Mehtali M., T. J. L. Experimental gene therapy: The transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice. AIDS. 11:1997;977-986.
35. Santini S. M., Spada M., Parlato S., Logozzi M., Lapenta C., Proietti E., Belardelli F., Fais S. Treatment of severe combined immunodeficiency (SCID) mice with anti-murine granulocyte monoclonal antibody improves human leukocyte xenotransplantation. Transplantation. 65:1998;416-427.
36. Shirazi Y., Pitha P. M. Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J. Virol. 66:1992;1321-1328.
37. Skillman D. R., Malone J. L., Decker C. F., Wagner K. F., Mapou R. L., Liao M. J., Testa D., Meltzer M. S. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: Evidence for drug safety, tolerance, and antiviral activity. J. Infect. Dis. 173:1996;1107-1114.
38. Su Y., Popik W., Pitha P. M. Inhibition of human immunodeficiency virus type 1 replication by a Tat-activated, transduced interferon gene: Targeted expression to human immunodeficiency virus type 1-infected cells. J. Virol. 69:1995;110-121.
39. Tough D. F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 272:1996;1947-1950.
40. Vieillard V., Cremer I., Lauret E., Rozenbaum W., Debre P., Autran B., De Maeyer E. Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th-1 type cytokine production and improves the proliferative response to recall antigens. Proc. Natl. Acad. Sci. USA. 94:1997;11595-11600.
41. Vieillard V., Lauret E., Maguer V., Jacomet C., Rozenbaum W., Gazzolo L., De Maeyer E. Autocrine interferon-beta synthesis for gene therapy of HIV infection: Increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals. AIDS. 9:1995;1221-1228.
42. Zagury D., Lachgar A., Chams V., Fall L. S., Bernard J., Zagury J. F., Bizzini B., Gringeri A., Santagostino E., Rappaport J., Feldman M., Burny A., Gallo R. C. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc. Natl. Acad. Sci. USA. 95:1998;3851-3856.
43. Zhang J. F., Hu C., Geng Y., Blatt L. M., Taylor M. W. Gene therapy with adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther. 3:1996;31-38.